5,8,11,14,17,20-六氧杂-2-氮杂二十三碳二酸 1-(9H-芴-9-基甲基)酯 | 882847-34-9

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: 5,8,11,14,17,20-六氧杂-2-氮杂二十三碳二酸 1-(9H-芴-9-基甲基)酯
• 中文别名: 5,8,11,14,17,20-六氧杂-2-氮杂二十三碳二酸1-(9H-芴-9-基甲基)酯；FMOC-21-氨基-4,7,10,13,16,19-六氧杂二十一烷酸；5,8,11,14,17,2-六氧杂-2-氮杂二十三碳二酸 1-(9H-芴-9-基甲基)酯
• 英文名称: fmoc-21-amino-4,7,10,13,16,19-hexaoxaheneicosanoic acid
• 英文别名: 1-(9H-fluoren-9-yl)-3-oxo-2,7,10,13,16,19,22-heptaoxa-4-azapentacosan-25-oic acid；3-[2-[2-[2-[2-[2-[2-(9H-fluoren-9-ylmethoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid
• CAS: 882847-34-9
• 化学式: C₃₀H₄₁NO₁₀
• 分子量: 575.656
• InChiKey: HEGZERUHBVYZPH-UHFFFAOYSA-N

物化性质

• 沸点：
  734.8±60.0 °C(Predicted)
• 密度：
  1.202±0.06 g/cm3 (20 ºC 760 Torr)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  41
• 可旋转键数：
  24
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  131
• 氢给体数：
  2
• 氢受体数：
  10

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C，密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Fmoc-nh-dpeg(6)-cooh
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Fmoc-nh-dpeg(6)-cooh
CAS number: 882847-34-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C30H41NO10
Molecular weight: 575.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

生物活性

Fmoc-NH-PEG6-CH2CH2COOH 是一种可降解的 ADC 连接子，用于抗体药物偶联物（ADC）合成。

性质	描述
可切片性	PEGs

体外研究

ADC 由一个通过连接子与 ADC 药物毒素相连的抗体组成。PROTAC 包含两个不同的配体，它们通过一个连接子连接；其中一个配体用于 E3 泛素连接酶，另一个用于靶蛋白。PROTAC 利用细胞内的泛素-蛋白酶体系统选择性降解目标蛋白质。

反应信息

• 作为反应物：
  描述：

  5,8,11,14,17,20-六氧杂-2-氮杂二十三碳二酸 1-(9H-芴-9-基甲基)酯 在 哌啶 作用下， 以 乙腈 为溶剂， 反应 0.33h， 生成 1-氨基-3,6,9,12,15,18-六氧杂二十一烷-21-酸
  参考文献：
  名称：

  神经元电压光学监测的化学遗传学方法。

  摘要：

  使用荧光指示剂对神经元电压进行光学监测是询问神经系统细胞和分子逻辑的有效方法。本文描述了一种基于尼罗红的半合成系留电压指示剂（STeVI1），当基因靶向神经元膜时，该指示剂表现出电压敏感性。这种环境敏感的探针可实现免清洗成像，并忠实地检测神经元的阈值以上和阈值以下活动。

  DOI：

  10.1002/anie.201812967
• 作为产物：
  描述：

  芴甲氧羰基-L-谷氨酸 1-叔丁酯 、 N-((1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-5-(1-methyl-1H-pyrazol-5-yl)-3-thiophenecarboxamide 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 5,8,11,14,17,20-六氧杂-2-氮杂二十三碳二酸 1-(9H-芴-9-基甲基)酯
  参考文献：
  名称：

  WO2008/98112

  摘要：

  公开号：

文献信息

• CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF
  申请人：PFIZER INC.

  公开号：US20130129753A1

  公开（公告）日：2013-05-23

  The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.

  本发明涉及细胞毒性五肽，其抗体药物偶联物，以及使用它们治疗癌症的方法。
• [EN] CALICHEAMICIN DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF<br/>[FR] DÉRIVÉS DE CALICHÉAMICINE ET CONJUGUÉS ANTICORPS-MÉDICAMENTS DE CEUX-CI
  申请人：PFIZER

  公开号：WO2018138591A1

  公开（公告）日：2018-08-02

  The present invention is directed to novel calicheamicin derivatives useful as payloads in antibody-drug-conjugates (ADC's), and to payload-linker compounds and ADC compounds comprising the same; to pharmaceutical compositions comprising the same and to methods for using the same to treat pathological conditions such as cancer.

  本发明涉及新型calicheamicin衍生物，用作抗体-药物偶联物（ADC）的有效载荷，以及包含相同有效载荷-连接剂化合物和ADC化合物；涉及包含它们的药物组合物以及使用它们治疗诸如癌症等病理状态的方法。
• [EN] DIRECTED CONJUGATION TECHNOLOGIES<br/>[FR] TECHNOLOGIES DE CONJUGAISON DIRIGÉE
  申请人：KLEO PHARMACEUTICALS INC

  公开号：WO2021102052A1

  公开（公告）日：2021-05-27

  Among other things, the present disclosure provides technologies for site-directed conjugation of various moieties of interest to target agents. In some embodiments, the present disclosure utilizes target binding moieties to provide high conjugation efficiency and selectivity. In some embodiments, provided technologies are useful for preparing antibody conjugates.

  本公开提供了用于将各种感兴趣的分子与目标剂进行定点偶联的技术。在某些实施方式中，本公开利用目标结合分子以提供高偶联效率和选择性。在某些实施方式中，所提供的技术可用于制备抗体偶联物。
• A sulfanyl-PEG derivative of relaxin-like peptide utilizable for the conjugation with KLH and the antibody production
  作者：Hidekazu Katayama、Masatoshi Mita

  DOI：10.1016/j.bmc.2016.05.068

  日期：2016.8

  is generally used as an antigen for producing specific antibodies. However, preparation of a disulfide-rich heterodimeric peptide–KLH conjugates is difficult. In this study, we developed a novel method for preparation of the conjugate, and applied it to the production of specific antibodies against the relaxin-like gonad-stimulating peptide (RGP) from the starfish. In this method, a sulfanyl group

  小肽-钥孔戚血蓝蛋白（KLH）缀合物通常用作产生特异性抗体的抗原。但是，制备富含二硫键的异二聚肽-KLH偶联物很困难。在这项研究中，我们开发了一种制备偶联物的新方法，并将其应用于从海星中产生针对松弛素样性腺刺激肽（RGP）的特异性抗体。在该方法中，在区域选择性二硫键形成反应之后，将与KLH缀合所必需的硫烷基基团特异性地引入肽中。使用缀合物，我们可以获得具有高抗体滴度的特异性抗体。该方法也可能用于产生针对具有二硫键交联作用的其他异二聚体肽的抗体，例如脊椎动物松弛素。
• Bifunctional cytotoxic agents
  申请人：Pfizer Inc.

  公开号：US10086085B2

  公开（公告）日：2018-10-02

  Cytotoxic dimers comprising CBI-based and/or CPI-based sub-units, antibody drug conjugates comprising such dimers, and to methods for using the same to treat cancer and other conditions.

  细胞毒性二聚体，包括基于CBI和/或基于CPI的亚单位，抗体药物偶联物包括这样的二聚体，以及使用同一方法治疗癌症和其他疾病。